Vor Biopharma Inc (VOR)
0.79
-0.01
(-0.77%)
USD |
NASDAQ |
Nov 22, 16:00
0.79
0.00 (0.00%)
After-Hours: 20:00
Vor Biopharma Cash from Financing (Quarterly): 0.041M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.041M |
| June 30, 2024 | -0.031M |
| March 31, 2024 | 0.096M |
| December 31, 2023 | 0.025M |
| September 30, 2023 | 0.176M |
| June 30, 2023 | 0.218M |
| March 31, 2023 | 2.519M |
| December 31, 2022 | 112.26M |
| September 30, 2022 | 4.075M |
| June 30, 2022 | 0.604M |
| Date | Value |
|---|---|
| March 31, 2022 | 0.20M |
| December 31, 2021 | 0.307M |
| September 30, 2021 | 0.201M |
| June 30, 2021 | -0.445M |
| March 31, 2021 | 232.85M |
| December 31, 2020 | 0.046M |
| September 30, 2020 | 0.526M |
| June 30, 2020 | 64.19M |
| March 31, 2020 | 17.76M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.445M
Minimum
Jun 2021
232.85M
Maximum
Mar 2021
22.93M
Average
0.218M
Median
Jun 2023
Cash from Financing (Quarterly) Benchmarks
| Organon & Co | -78.00M |
| NovaBay Pharmaceuticals Inc | 2.089M |
| Palatin Technologies Inc | -0.127M |
| iBio Inc | -0.162M |
| Theriva Biologics Inc | 3.716M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -23.28M |
| Cash from Investing (Quarterly) | -0.034M |
| Free Cash Flow | -99.89M |
| Free Cash Flow Per Share (Quarterly) | -0.3406 |
| Free Cash Flow Yield | -185.5% |